LLY on XNYS, Health Care, Eli Lilly & Co., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue rose 39% to $24.4B and 12-month profit rose 50% to $27.6B.
WatchVisa applications for foreign specialists fell 32%, to 350 from 517
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
expected around 3 Feb 2027 (an estimate: a year ago it reported on 4 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $24.4B, net income $6.5B.
31 Dec 2021RevenueNet incomeNet losstallest bar $24.4B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$24.4B
$6.5B
30 Jun 2026
$23.0B
$7.1B
31 Mar 2026
$19.8B
$7.4B
31 Dec 2025
$19.3B
$6.6B
30 Sep 2025
$17.6B
$5.6B
30 Jun 2025
$15.6B
$5.7B
31 Mar 2025
$12.7B
$2.8B
31 Dec 2024
$13.5B
$4.4B
30 Sep 2024
$11.4B
$970.3M
30 Jun 2024
$11.3B
$3.0B
31 Mar 2024
$8.8B
$2.2B
31 Dec 2023
$9.4B
$2.2B
30 Sep 2023
$9.5B
-$57.4M
30 Jun 2023
$8.3B
$1.8B
31 Mar 2023
$7.0B
$1.3B
31 Dec 2022
$7.3B
$1.9B
30 Sep 2022
$6.9B
$1.5B
30 Jun 2022
$6.5B
$952.5M
31 Mar 2022
$7.8B
$1.9B
31 Dec 2021
$8.0B
$1.7B
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$86.5B
$59.4B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+46%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$27.6B
$18.4B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$30.81
$20.44
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
83.6%
83.0%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
31.9%
31.0%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
86.1%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$4.9B
$9.9B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$49.5B
$42.5B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$44.6B
$32.6B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
1.2
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$42.81
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
45.9
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
14.7
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
15.2
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
31.5
2.0
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
0.46%
2.5%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$7.0M
bought $0, sold $7.0M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+1.0%
4,570 13F filers vs 4,526
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
82%
775.6M shares held by 13F filers (30 Sep 2026) of 940.7M outstanding (26 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
0.8%
7.2M shares sold short (30 Oct 2026) of 940.7M outstanding (26 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.7
7.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+3.6%
7.0M shares sold short in the report before, 7.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
36%
36% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 40%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
-32%
350 vs 517 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+39%
$24.4B vs $17.6B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$282K
the 12 months before: $0
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$12.5M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
147
147 articles in the last 7 days; its usual week has 21 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
7.0×
147 articles in the last 7 days; its usual week has 21.
Price $1,347.11 on 20 Nov 2026, +29% over 12 months (12-month range $851.21 to $1,443.50)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $372.5M in the last 12 months (the 12 months before: -$4.2B).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 350 published in the last 12 months, -32% on the 12 months before.Revenue per quarter. Revenue $24.4B in the latest quarter, +39% on a year earlier.Capital spending per quarter. Capital spending $617.2M in the latest quarter, +83% on a year earlier.Institutional holders (13F filers). 4,570 13F filers reported holding it in the latest 13F quarter, +23% on a year earlier.Federal obligations. Federal obligations: $57K published in the last 12 months, -75% on the 12 months before.Lobbying spend. Lobbying spend: $12.5M published in the last 12 months, +15% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $8.0B; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $7.8B, +15% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $6.5B, -3.7% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $6.9B, +2.5% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $7.3B, -8.7% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $7.0B, -11% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $8.3B, +28% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $9.5B, +37% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $9.4B, +28% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $8.8B, +26% on a year earlier; public on 1 May 2024
Quarter ended 30 Jun 2024: $11.3B, +36% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $11.4B, +20% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $13.5B, +45% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $12.7B, +45% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $15.6B, +38% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $17.6B, +54% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $19.3B, +43% on a year earlier; public on 13 Feb 2026
Quarter ended 31 Mar 2026: $19.8B, +56% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $23.0B, +48% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $24.4B, +39% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $365.4M, +22% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $371.0M, -2.7% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $617.2M, +83% on a year earlier; public on 2 Nov 2022
Institutional holders (13F filers)
31 Dec 2021 report: 2,034; public on 14 Feb 2022
31 Mar 2022 report: 2,187; public on 16 May 2022
30 Jun 2022 report: 2,281; public on 15 Aug 2022
30 Sep 2022 report: 2,267; public on 14 Nov 2022
31 Dec 2022 report: 2,430; public on 14 Feb 2023
31 Mar 2023 report: 2,430; public on 15 May 2023
30 Jun 2023 report: 2,577; public on 14 Aug 2023
30 Sep 2023 report: 2,727; public on 14 Nov 2023
31 Dec 2023 report: 2,999; public on 14 Feb 2024
31 Mar 2024 report: 3,245; public on 15 May 2024
30 Jun 2024 report: 3,347; public on 14 Aug 2024
30 Sep 2024 report: 3,435; public on 14 Nov 2024
31 Dec 2024 report: 3,646; public on 14 Feb 2025
31 Mar 2025 report: 3,737; public on 15 May 2025
30 Jun 2025 report: 3,730; public on 14 Aug 2025
30 Sep 2025 report: 3,712; public on 14 Nov 2025
31 Dec 2025 report: 4,204; public on 17 Feb 2026
31 Mar 2026 report: 4,240; public on 15 May 2026
30 Jun 2026 report: 4,526; public on 14 Aug 2026
30 Sep 2026 report: 4,570; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $329.8M published
Month from 1 Feb 2022: $1.3B published
Month from 1 Apr 2022: $0 published
Month from 1 May 2022: $1.1B published
Month from 1 Sep 2022: $273.8M published
Month from 1 Nov 2022: $0 published
Month from 1 Dec 2022: $109.5M published
Month from 1 May 2023: $0 published
Month from 1 Oct 2025: $230K published
Month from 1 May 2026: $52K published
Month from 1 Aug 2026: $2K published
Month from 1 Sep 2026: $2K published
Lobbying spend
Quarter from 1 Jan 2022: $2.4M published
Quarter from 1 Apr 2022: $1.7M published
Quarter from 1 Jul 2022: $2.2M published
Quarter from 1 Oct 2022: $1.4M published
Quarter from 1 Jan 2023: $2.2M published
Quarter from 1 Apr 2023: $1.7M published
Quarter from 1 Jul 2023: $1.8M published
Quarter from 1 Oct 2023: $2.4M published
Quarter from 1 Jan 2024: $2.7M published
Quarter from 1 Apr 2024: $1.9M published
Quarter from 1 Jul 2024: $2.6M published
Quarter from 1 Oct 2024: $1.9M published
Quarter from 1 Jan 2025: $2.0M published
Quarter from 1 Apr 2025: $3.5M published
Quarter from 1 Jul 2025: $2.9M published
Quarter from 1 Oct 2025: $2.5M published
Quarter from 1 Jan 2026: $2.4M published
Quarter from 1 Apr 2026: $3.9M published
Quarter from 1 Jul 2026: $3.4M published
Quarter from 1 Oct 2026: $2.8M published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is wikipedia page views (human, all devices) at 11K (week of 9 Nov 2026), 1.3× its normal week; higher than 84% of its own history.
H-1B/E-3 applications change: had 24 H-1B/E-3 visa applications certified in February 2026, 2.2× the same month last year Public on 29 Jun 2026.
Reported lobbying spend: $2.8M in Q3 2026, $3.4M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
The Simmons & Russell Group, LLCfor Eli Lilly And Company
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program. Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169. Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.36; Issues related to tax legislation; Tax Relief for American Families and Workers Act of 2024, H.R.7024.Pharmacy, Taxation
Two or more unrelated kinds of records unusual within 30 days
2 Sep 2025confirmed
Confirmed across sources Hiring and Insiders
Eli Lilly(LLY): had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings), while it had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year. Two unrelated kinds of activity within 20 days.
Insiders: Clustered insider buying, became public on 13 Aug 2025
Hiring: H-1B/E-3 applications change, became public on 31 Aug 2025
June 2025 against the 5 months before it.
this monthearliernormal: 6See the evidence (2 changes)
Insiders: Clustered insider buying became public on 13 Aug 2025
Eli Lilly had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings).
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Hiring: H-1B/E-3 applications change became public on 31 Aug 2025
Eli Lilly had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.
This period
142 (June 2025)
Normal month (median of 5 earlier)
6
Typical spread (median absolute deviation)
6
How far from its usual level
+15.3
Same month last year
69
History used
2,079 days
June 20255 earlier monthsnormal: 6
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
28 Mar 2023confirmed
Confirmed across sources Attention and Short interest and volume
Eli Lilly(LLY): drew 13K Wikipedia page views in the week of 27 Feb 2023, 3.2× the same week last year, while it had 8.1M shares sold short in the 15 Mar 2023 report, 1.2× the same report last year. Two unrelated kinds of activity within 21 days.
Attention: Wikipedia attention spike, became public on 7 Mar 2023
Short interest and volume: Short interest spike, became public on 25 Mar 2023
The week of 27 Feb 2023 against the 26 weeks before it.
this weekearliernormal: 5,175See the evidence (2 changes)
Attention: Wikipedia attention spike became public on 7 Mar 2023
Eli Lilly drew 13K Wikipedia page views in the week of 27 Feb 2023, 3.2× the same week last year.
This period
13K (the week of 27 Feb 2023)
Normal week (median of 26 earlier)
5,175
Typical spread (median absolute deviation)
342
How far from its usual level
+14.7
Same week last year
4,012
History used
1,524 days
the week of 27 Feb 202326 earlier weeksnormal: 5,175
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Short interest and volume: Short interest spike became public on 25 Mar 2023
Eli Lilly had 8.1M shares sold short in the 15 Mar 2023 report, 1.2× the same report last year.
This period
8.1M (the 15 Mar 2023 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
394K
How far from its usual level
+4.7
Same report last year
6.6M
History used
1,902 days
the 15 Mar 2023 report24 earlier reportsnormal: 5.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Nov 2022confirmed
Confirmed across sources Attention and Filings + Financials
Eli Lilly(LLY): spent $617.2M on capital projects in the quarter ended 30 Sep 2022, 1.8× the same quarter last year, while it drew 49K Wikipedia page views in the week of 7 Nov 2022, 12× the same week last year. Two unrelated kinds of activity within 7 days.
Financials: Quarterly capital spending jump, became public on 8 Nov 2022
Attention: Wikipedia attention spike, became public on 15 Nov 2022
The quarter ended 30 Sep 2022 against the 8 quarters before it.
this quarterearliernormal: $351.1MSee the evidence (2 changes)
Financials: Quarterly capital spending jump became public on 8 Nov 2022
Eli Lilly spent $617.2M on capital projects in the quarter ended 30 Sep 2022, 1.8× the same quarter last year.
This period
$617.2M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$351.1M
Typical spread (median absolute deviation)
$36.1M
How far from its usual level
+5.0
Same quarter last year
$336.8M
History used
1,279 days
the quarter ended 30 Sep 20228 earlier quartersnormal: $351.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Attention: Wikipedia attention spike became public on 15 Nov 2022
Eli Lilly drew 49K Wikipedia page views in the week of 7 Nov 2022, 12× the same week last year.
This period
49K (the week of 7 Nov 2022)
Normal week (median of 26 earlier)
4,542
Typical spread (median absolute deviation)
285
How far from its usual level
+98.3
Same week last year
4,123
History used
1,412 days
the week of 7 Nov 202226 earlier weeksnormal: 4,542
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
had 24 H-1B/E-3 visa applications certified in February 2026, 2.2× the same month last year.
Same month last year: 11; its normal month is 7.
See the evidence
This period
24 (February 2026)
Normal month (median of 5 earlier)
7
Typical spread (median absolute deviation)
2
How far from its usual level
+5.7
Same month last year
11
History used
2,322 days
February 20265 earlier monthsnormal: 7
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
had 48 H-1B/E-3 visa applications certified in November 2025, 3.0× the same month last year.
Same month last year: 16; its normal month is 8.
See the evidence
This period
48 (November 2025)
Normal month (median of 5 earlier)
8
Typical spread (median absolute deviation)
6
How far from its usual level
+4.5
Same month last year
16
History used
2,232 days
November 20255 earlier monthsnormal: 8
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
saw 319 13F filers open a new position in the quarter ended 31 Dec 2025, 2.2× the same quarter last year.
Same quarter last year: 146; its normal quarter is 170.
See the evidence
This period
319 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
170
Typical spread (median absolute deviation)
14
How far from its usual level
+7.2
Same quarter last year
146
History used
4,475 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 170
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 26 H-1B/E-3 visa applications certified in August 2025, 2.0× the same month last year.
Same month last year: 13; its normal month is 10.
See the evidence
This period
26 (August 2025)
Normal month (median of 5 earlier)
10
Typical spread (median absolute deviation)
3
How far from its usual level
+3.6
Same month last year
13
History used
2,141 days
August 20255 earlier monthsnormal: 10
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings), while it had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year. Two unrelated kinds of activity within 20 days.
See the evidence (2 changes)
Insiders: Clustered insider buying became public on 13 Aug 2025
Eli Lilly had 5 insiders buy $2.9M of its shares on the open market within 30 days (5 filings).
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Hiring: H-1B/E-3 applications change became public on 31 Aug 2025
Eli Lilly had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.
This period
142 (June 2025)
Normal month (median of 5 earlier)
6
Typical spread (median absolute deviation)
6
How far from its usual level
+15.3
Same month last year
69
History used
2,079 days
June 20255 earlier monthsnormal: 6
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
31 Aug 2025Hiring change
had 142 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.
Same month last year: 69; its normal month is 6.
See the evidence
This period
142 (June 2025)
Normal month (median of 5 earlier)
6
Typical spread (median absolute deviation)
6
How far from its usual level
+15.3
Same month last year
69
History used
2,079 days
June 20255 earlier monthsnormal: 6
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 57 H-1B/E-3 visa applications certified in May 2024, 3.8× the same month last year.
Same month last year: 15; its normal month is 10.5.
See the evidence
This period
57 (May 2024)
Normal month (median of 4 earlier)
10.5
Typical spread (median absolute deviation)
7.5
How far from its usual level
+4.2
Same month last year
15
History used
1,684 days
May 20244 earlier monthsnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
drew 13K Wikipedia page views in the week of 8 Jan 2024, 2.2× the same week last year.
Same week last year: 5,769; its normal week is 7,180.
See the evidence
This period
13K (the week of 8 Jan 2024)
Normal week (median of 26 earlier)
7,180
Typical spread (median absolute deviation)
700
How far from its usual level
+5.4
Same week last year
5,769
History used
1,839 days
the week of 8 Jan 202426 earlier weeksnormal: 7,180
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Showing the newest 40 of 159 entries; narrow the window or the kind of data to see older ones.
Not listed: 532 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000059478
Ticker
LLY
Domain
lilly.com
Employer name
Eli Lilly and Company, Lilly USA, LLC (2 unverified)
Fein
26-3011712 (1 unverified)
Hq location
IN|INDIANAPOLIS|46285 (1 unverified)
Lobbying client
eli lillly, eli lilly, eli lilly and company fka lilly usa, tiber creek health strategies inc on behalf of eli lilly
Name
Adverum Biotechnologies, Inc, Adverum NC, LLC, Akouos, Inc, Alnara Pharmaceuticals, Inc and 153 more
Uei
UHHVNTY54K68
Wikidata
Q632240
Wikipedia
Eli Lilly and Company
DOL H-1B labor condition applications and PERM certifications1380 data points21 Oct 2019 to 21 Sep 2026
Federal lobbying disclosures (LDA)123 records, 279 data points1 Jan 1999 to 30 Sep 2026
SEC Form 13F institutional holdings11 records, 481 data points30 Jun 2013 to 13 Nov 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)138 records19 Feb 2016 to 29 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1039 data points31 Dec 2006 to 26 Oct 2026
SEC Form 4 insider transactions444 records, 1576 data points2 Feb 2016 to 3 Nov 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards5 records, 105 data points25 Oct 2007 to 1 Sep 2026
WARN layoff notices (state labor agencies)1 record, 3 data points25 Sep 2017 to 1 Oct 2017
Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026